Sign In
Buy ILMN
$170.93
+8.38 (+5.16%)
At Close: Jun 03, 2026
Coronavirus Mutations: Why The Battle Against Covid Is Just Beginning
07:00am, Friday, 26'th Feb 2021
The battle against Covid-19 is about to get uglier. Coronavirus mutations threaten to undercut a year's worth of work upholding Covid stocks like Pfizer, Moderna and Regeneron Pharmaceuticals.
CHRS or ILMN: Which Is the Better Value Stock Right Now?
12:53pm, Thursday, 18'th Feb 2021
CHRS vs. ILMN: Which Stock Is the Better Value Option?
A 'Bio Force' Is Needed to Stop Virus, Says Illumina CEO
10:01am, Thursday, 18'th Feb 2021
Feb.17 -- Illumina chief executive officer Francis deSouza discusses the company's impressive start to the year and why a "bio force" is needed post pandemic to ensure viruses don't wreak further havo
Illumina (ILMN) Sequencing & Microarray Sales Hurt by Pandemic
12:08pm, Wednesday, 17'th Feb 2021
Seasonality in DTC functionality also continues to erode Illumina's (ILMN) microarray sales.
Illumina Earnings, Forward Guidance Strengthen Biotech ETFs
03:38pm, Friday, 12'th Feb 2021
Biotechnology sector-related exchange traded funds strengthened after Illumina (NasdaqGS: ILMN) announced better-than-expected quarterly earnings and an optimistic 2021 outlook. On Friday, the VanEck
Why These 2 Hot Nasdaq Stocks Are Soaring Friday
02:52pm, Friday, 12'th Feb 2021
Even as markets took a pause, there's still plenty of action in individual stock names.
Illumina Stock: Covid, Bioterrorism And Grail Just Sent It To A Record
01:31pm, Friday, 12'th Feb 2021
Illumina stock rocketed to a record Friday after the company boosted its first quarter outlook on the growing need for DNA sequencing to surveil Covid-19 mutations and vaccines. The post Illumina Stoc
Illumina CEO on the hunt to find Covid-19 variants
09:18am, Friday, 12'th Feb 2021
Francis deSouza, CEO of Illumina, joins CNBC's Meg Tirrell to discuss the company's earnings and business into Covid-19 sequencing.
Illumina's (ILMN) CEO Francis deSouza on Q4 2020 Results - Earnings Call Transcript
10:55pm, Thursday, 11'th Feb 2021
Illumina's (ILMN) CEO Francis deSouza on Q4 2020 Results - Earnings Call Transcript
Illumina (ILMN) Q4 Earnings and Revenues Beat Estimates
06:09pm, Thursday, 11'th Feb 2021
Illumina (ILMN) delivered earnings and revenue surprises of 0.83% and 0.35%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
A Preview Of Illumina's Earnings
10:47am, Wednesday, 10'th Feb 2021
Illumina (NASDAQ:ILMN) will be releasing its next round of earnings this Thursday, February 11. For all of the relevant information, here is your guide for Thursday's Q4 earnings announcement.
Why Shares of Illumina Rose 15.3% in January
08:42am, Monday, 08'th Feb 2021
The genomics leader got a boost from identifying new COVID variants, and won a patent lawsuit.
Week In Review: Junshi Signs $1.1 Billion Deal For U.S.-Canada Rights To PD-1
03:38pm, Sunday, 07'th Feb 2021
Week In Review: Junshi Signs $1.1 Billion Deal For U.S.-Canada Rights To PD-1
SAN DIEGO--(BUSINESS WIRE)--Illumina announced support for national pilot study in Belgium to evaluate impact of comprehensive genomic profiling for late stage cancer.
Illumina (ILMN) New Collaboration to Aid Genomics Startups
10:37am, Monday, 01'st Feb 2021
Illumina (ILMN) partners with Sequoia Capital China to set up a genomics-focused startup incubator in China.
